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Purpose. To ascertain wet AMD (wAMD) management patterns in Spain.Methods. A two-round Delphi study conducted through
a questionnaire-based survey designed from literature review and validated by an independent Steering Committee. Results.
Forty-nine retina specialists experienced in wAMD participated by answering the two-round study questionnaire. Retina
specialists are the main responsible for wAMD diagnosis and monitoring, including visits and associated procedures, with a
median time per visit of 15minutes. Standard treatment strategies are based on anti-VEGF administration, including standard
loading dose administration followed by maintenance with aflibercept or ranibizumab (81% of patients). Although treat and
extend (T&E) dosing strategy is considered as optimal for wAMDmanagement (78% of the panelists), the main routine healthcare
limitations (i.e., visits overload, reduced staff, short visit time, coordination issues, lack of facilities) conduct to self-defined
“flexible” strategies, based on T&E and pro-re-nata (PRN) protocols. Conclusion. Proactive treatment patterns (T&E) are the
preferred ones by the retina specialists in Spain. However, their proper implementation is difficult due to healthcare resource
limitations, as well as organisation and logistic issues. .e use of anti-VEGF agents with longer duration of action could facilitate
the use of strict T&E approaches according to routine clinical practices.
1. Introduction
Age-related macular degeneration (AMD) is a chronic,
progressive, and severe disease of the central retina and is the
main cause of irreversible blindness in the Western world
and Asia-Pacific countries [1, 2]. Up to date, 8.7% of the
worldwide population has AMD [3]. .e wet form of the
disease is responsible for more than 90% of the severe central
visual acuity (VA) loss associated with AMD [4].
Wet AMD (wAMD) has no cure even though an
appropriated treatment could delay disease progression,
avoiding the negative impact of vision loss in the quality of
life of these patients [5, 6]. According to the most recent
AMD guidelines [7, 8], the intravitreal administration of
antivascular endothelial growth factor agents (anti-VEGF)
constitutes the standard of care for wAMD patients due to
the promising results provided by these therapies during
clinical development [9].
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However, the success of anti-VEGF therapy is closely
linked to strict intravitreal treatment patterns [10] that seem
not to be properly addressed in routine clinical practice
[11, 12], conducting to poorer outcome results for wAMD
patients than the expected according to clinical trials
[13, 14]. During the first year of treatment, results in real
world practice seem to be closer to those reported for each
drug [11, 12]. However, during the second year, treatment
dosing increases in “flexibility” due to the rise in the amount
of patients, stress of monthly assessments, and economic
burden, having a negative impact on outcomes and be-
coming an especially relevant issue [11, 12].
Healthcare limitations are a reality in routine clinical
practice. However, strict management protocols should be
considered mandatory to guarantee optimal results for
wAMD patients, involving drug selection and dosing
strategy [15]. In order to choose the most appropriate
therapeutic approach, it is necessary to consider several
factors including patient profile, disease characteristics, drug
access, healthcare resources available, management pro-
tocols, and healthcare burden, among others [14, 16]. In this
regard, a Delphi study was conducted to describe wAMD
management in Spain based on anti-VEGF administration.
Challenges, limitations, and preferences of the retina spe-
cialists were assessed to identify the most appropriate
treatment and dosing strategies for these patients in routine
clinical practice.
2. Methods
2.1. Study Design and Development. According to the study
objectives, a two-round Delphi methodology [16–18] was
considered as the most appropriate due to its capability to
define answer consensus and ratification. An ad hoc study
questionnaire was developed after an exhaustive literature
search onwAMDmanagement and anti-VEGF evidence, being
analysed and validated by a Steering Committee conformed by
5 ophthalmologists with retina expertise, from 5 different
Spanish centres. .e questionnaire included a final set of 38
questions, comprising 4 main sections: (i) participant profile,
(ii) general management of wAMD, (iii) wAMDdiagnosis, and
(iv) wAMD treatment. Treatment strategy options were cate-
gorized as “strict” or “flexible” according to the agreement level
with the recommended patterns [7, 8] and product technical
conditions [10]. .us, strict pro-re-nata (PRN) would involve
monthly monitoring and immediate on-demand treatment
after loading dose, while strict treat and extend (T&E) would
involve regular preplanned treatment administration after
loading dose administration, including progressive increase in
the injection periods. Flexible strategies were considered as
deviations of the standard strategies, mainly represented by an
irregular monitoring and/or treatment of the patients and
attributable to routine clinical practice needs.
.e study questionnaire was designed to be filled online by
50 retina specialists selected according to the following criteria:
(i) ≥5 years in wAMD management in Spain and (ii) to be the
current responsible for wAMD management in the centre
(including treatment administration and follow-up). Main
contact for study recruitment was conducted by email, and the
interested participants signed an agreement, committing to
answer both Delphi rounds (approximately 20minutes each).
.e access link to the questionnaire was emailed to each
participant, together with a personal access individually pro-
vided in a separated email. All questions were designed to be
answered considering the experience of each panelist according
to their routine clinical practice. Questions focused on treat-
ment strategy prioritization were rated by the panelists, and
each rank level was converted into scoring punctuation,
providing mean priority scores per option.
In Spain, there are more than 300 hospitals with oph-
thalmology service and more than 600 retina specialists ex-
perienced in the management of wAMD. Since the sample size
for a Delphi panel depends on study objectives, available re-
sources, and panel nature (ranging from 10–15 for homoge-
neous groups to several hundreds in heterogeneous groups
[19]), a sample of 50 retina specialists (a homogeneous group of
healthcare professionals with different realities) was considered
as enough for this study purpose, prioritizing those from the
biggest hospitals of the different Spanish regions. In addition,
all participants had been previously involved in wAMD and
Delphi studies in Spain, being experienced not only in the
disease, but in methodology [16].
.e same study questionnaire was used in both rounds,
with minor adaptations, so that answers could be reviewed,
rechecked, and confirmed, providing robustness to the final
study results. .e first Delphi round was carried out in April
2017, and the second in June 2017. .e results collected in
the first round were discussed by the Steering Committee,
and some items were slightly reworded for clarification.
Aggregated results were provided to the panelists before the
second Delphi round, where the empty questionnaire was
resent to the participants to be responded (none of the
participants had access to their previous individual answers).
Consensus was predefined as homogeneity or consistency of
opinions among experts and understood as a reduction of
answer dispersion between data provided in the first and
second Delphi rounds.
2.2. Result Analysis. A descriptive analysis was conducted
per outcome, providing number of responses (n) and per-
centage (%), mean result, and standard deviation (SD). For
abnormal outcomes, median and confidence interval were
calculated. Results of the second round were used as the final
validated data of the study. Considering the nature of the
questions, as well as the different scoring systems used in the
study, consensus was reached with ≥60% of agreement per
item. Additionally, the dispersion in the answers was also
considered, being considerably lower than in first-round
responses.
3. Results
3.1. Participant Profile. A total of 49 retina specialists from
all around Spain participated in both Delphi rounds. Mean
(SD) age of participants was 49 (7) years, and they accounted
for a mean (SD) of 16 (6) years of experience in the wAMD
patients’ management. Most participants (82%) were
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frequently involved in ophthalmology clinical trials (mean
(SD) 3.7 (2.7) trials per year).
3.2. Burden of wAMD Management in the Ophthalmology
Services. wAMD management represents 25% (18) of the
ophthalmology visits in Spain, with a median time (P25–
P75) per visit of 15minutes (10–15minutes). .is time
considers the average time per patient including treatment
administration and other procedures, when needed, and
excluding patient waiting time.
wAMD patients are usually referred to the retina spe-
cialist by other medical doctors (40%), from the same centre
or related (i.e., ophthalmologists from primary care), as well
as from the emergency units (32%). .e retina specialist is
the main responsible for disease diagnosis and patient
monitoring, being involved in all the procedures performed
to the patient (except for microperimetry, taken by the
imaging technicians). Together with the retina specialist, the
specialty trainee is responsible for slit lamp fundus exami-
nation, fluorescein angiography, indocyanine green angi-
ography (ICGA), optical coherence tomography (OCT),
angio-OCT, and fundus autofluorescence. According to the
experience of the study participants, optometrists and nurses
usually provide support with Snellen and/or ETDRS (Early
Treatment Diabetic Retinopathy Study) tests even though
they could, eventually, also provide support in other tasks
such as OCT, fluorescein angiography, angio-OCT, or
fundus autofluorescence.
wAMD diagnosis is usually done by slit lamp fundus
examination (98%), OCT (94%), Snellen test (82%), and/or
fluorescein angiography (85%) (Figure 1(a)). Except for
fluorescein angiography, these tests are frequently repeated
during follow-up visits, to check disease progression and to
assess treatment effectiveness, with a mean frequency of
2months (Figure 1(b)).
3.3. Intravitreal Administration Procedure. Most of the
panelists (63%) reported to have specific protocols for
wAMD management, being mandatory in 10% of cases.
National SERV (Sociedad Española de Retina y Vitreo)
guidelines [8] were considered as key reference documents
for 55% of the participants, while EURETINA guidelines [7]
were mainly considered as supportive references for wAMD
management (51% of the panelists).
Intravitreal administration by one-stop visit was possible
in 57% of participant centres. Main limitations to conduct
this practice were due to lack of staff (57%), short visit time
(52%), limited access to the drug during the visit (52%), and
facility issues (52%). Access to anti-VEFG drugs was not
identified as issue, with the exception of sodium pegaptanib,
restricted in 71% of the participant centres.
3.4. wAMD Treatment Pathways
3.4.1. Loading Dose. With independence of the patient
profile or lesion type, most of the panelists (92%) referred the
use of a standard loading dose for anti-VEGF treatment
initiation (three monthly injections), using as drug choice
aflibercept in 40% of the patients, ranibizumab in 36%, and
bevacizumab in 23%.
According to the experience of the panelists, 94% (SD
5%) of patients would complete appropriately the loading
dose schedule.
3.4.2. MaintenanceAerapy. Maintenance therapy was done
with the same anti-VEGF agent used during the loading
phase period. During the first and second year, 81% of the
patients would be treated with aflibercept and ranibizumab
(first year: 43% and 38; second year: 45% and 36%, re-
spectively). .e remaining proportion of patients was
treated with bevacizumab. No patients were treated with
sodium pegaptanib.
Overall, no major safety concerns were reported with
anti-VEGF therapies, even when planned and used for a long
time. According to the experience of the participants, 15% of
the patients require to stop treatment (19% bevacizumab,
12% ranibizumab, and 10% aflibercept), mainly due to in-
sufficient treatment response, other clinical criteria, and
issues with patient follow-up (Figure 2(a)).
Moreover, around 23% of patients need to be switched to
another agent (24% bevacizumab, 23% ranibizumab, and
15% aflibercept), usually because of an insufficient response
to the initial treatment (Figure 2(b)). In these cases, the most
frequent switch was to aflibercept or ranibizumab,
depending on the first drug used.
3.4.3. Treatment Dosing Strategy. .e most frequently re-
ported treatment regimens for wAMD patients were T&E
and PRN (Figure 3). During the first year, the planned
maintenance dosing strategies were strict T&E and PRN,
whenever possible (Figure 3(a)). However, during the sec-
ond year, these strategies needed to be adapted to a defined
as “flexible” scheduling (Figure 3(b)).
According to the 39% and 37% of the panelists, the
treatment strategies used during the first and second year,
respectively, would not be considered as optimal. In the
opinion of the 78% of participants, the most appropriate
treatment strategy for the whole wAMD treatment should be
strict T&E approach (Figures 3(c) and 3(d)), with in-
dependence of the patient profile or lesion type. .e only
exception would be identified in case of adverse events risk,
where PRN would be considered the most appropriate
approach (Table 1).
3.5. Challenges and Limitations for wAMD Management on
RoutineClinical Practice. According to the experience of the
study participants, treatment choice would be conditioned
by healthcare overload (understood as lack of agenda for an
appropriate patient monitoring according to the strict
dosing strategy selected), lack of staff, healthcare
coordination issues, and prolonged waiting time for
intravitreal injection administration (Figure 4). In addition,
the main limitations for an optimal treatment strategy
achievement would be mainly related with organisational
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problems, confusion over scheduling, and healthcare re-
source availability (Figure 5).
4. Discussion
According to the main clinical guidelines and wAMD
management protocols [7, 8], anti-VEGF therapies are the
gold standard for wAMD treatment, and, actually, these are
the therapies used on routine clinical practice in Spain.
However, as it was evidenced in previous studies [13, 14],
these good practices seem not to be reected on outcomes,
achieving suboptimal results compared with the expected by
the anti-VEGF clinical trials [12, 20–22]. e main reason
for these dierent results could be the dierence in the
management patterns among the strict injection protocols
used in clinical trials and the adapted injection patterns used
in routine clinical practice [16, 23–25] and identied as
“exible” in our study.
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Figure 1: Use of diagnosis tests in routine clinical practice of the participant centres (n 49), in patients with wAMD in Spain (multiple-
choice question): (a) diagnosis tests; (b) time interval from wAMD diagnosis to rst visit.
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In general terms, according to the information provided
by the study panelists, in Spain, wAMD management is
mainly done according to the national and international
retina guidelines (SERV and EURETINA) [7, 8] even though
adapted to specic management protocols that could vary
according to the healthcare resources and limitations of each
centre and that could conduct to those “exible” strategies.
A common fact among healthcare centres is that the
main responsible for wAMD management is the retina
specialist, involved from diagnosis to long-term moni-
toring, and including standard visits and associated
procedures. Retina specialist tasks are supported by
specialist trainees and, when available, by other health-
care sta such as nurse or optometrists. is complete
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Figure 2: Prioritization made by the retina specialists regarding the main reasons for (a) anti-VEGF treatment dropout (7 points score) and
(b) anti-VEGF switch (5 points score).
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involvement of the retina specialist in the patientmanagement,
although an advantage in terms of healthcare assistance quality
for the patient, represents an important overload for the
specialist, that nally conduct to a limitation for an optimal
disease management and one-stop procedures.
In terms of treatment, the standard management of the
patients is anti-VEGF therapies, according to the recom-
mended practices [7, 8]. e main drugs used in routine
clinical practice, considering all the treatment pathway, are
aibercept and ranibizumab, for both, loading dose and
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Figure 3: Treatment strategies prioritized by the retina experts (6 points score) (a) according to use during the rst year of treatment,
(b) according to use during the second year of treatment, (c) when considered as optimal for the rst year of treatment, and (d) when
considered as optimal for the second year of treatment.
Table 1: Panelists opinion (n 49) regarding anti-VEGF treatment strategies considered as optimal for wAMD management according to
patient prole and lesion type in Spain.
PRN strict PRN exible Fixed dose T&E strict T&E exible No treatment
Patient characteristics; opinion, n (%)
Very low initial VA 12 (24%) 6 (12%) 3 (6%) 25 (51%) 7 (14%) 6 (12%)
Good initial VA 10 (20%) 1 (2%) 9 (18%) 34 (69%) 3 (6%) 0 (0%)
Aged patient 7 (14%) 2 (4%) 9 (18%) 24 (49%) 13 (27%) 1 (2%)
Single eye 14 (29%) 0 (0%) 11 (22%) 34 (69%) 1 (2%) 0 (0%)
Adverse events risk 16 (33%) 9 (18%) 1 (2%) 12 (24%) 10 (20%) 2 (4%)
Centre accessibility (distance) 4 (8%) 4 (8%) 7 (14%) 26 (53%) 10 (20%) 0 (0%)
Protocol/centre guidelines 12 (24%) 3 (6%) 8 (16%) 27 (55%) 10 (20%) 0 (0%)
Patient cost 13 (27%) 10 (20%) 4 (8%) 15 (31%) 11 (22%) 1 (2%)
Disease characteristics (type of lesion); opinion, n (%)
Neovascularisation type 1 10 (20%) 0 (0%) 8 (16%) 37 (76%) 5 (10%) 0 (0%)
Neovascularisation type 2 13 (27%) 0 (0%) 10 (20%) 37 (76%) 2 (4%) 0 (0%)
Neovascularisation type 3 15 (31%) 0 (0%) 13 (27%) 33 (67%) 3 (6%) 0 (0%)
VA: visual acuity.
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treatment maintenance, and being considered as the most
appropriated for all patient’s management, with in-
dependence of the patient prole or the type of lesion.
According to the information provided by the study
panelists, although no signicant issues are evidenced for
the loading dose (successful administration in more than
90% of the patients), important management issues for long-
term schedules are identied, being mainly related with
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experience of the 49 retina specialists participating in the Delphi study.
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healthcare resource limitations, as well as their own
healthcare overload and staff restrictions.
As it was anticipated in 2014 [16] and aligned with the
available evidence [16, 24, 26, 27], most of the retina spe-
cialists participating in the study (78%) agreed in the aim for
using T&E strategies in their routine clinical practice.
However, healthcare reality and the limited resources
available conduct to a need for self-defined “flexible”
strategies that could be a critical issue for achieving optimal
healthcare results in routine clinical practice.
Traditionally, reactive regimens for wAMD management
were the standard procedures in Spain [8]. Strict PRN pattern
was the reference protocol used in most centres even though
not to be realistically conducted [12, 16]. Strict PRN protocols
are linked to regular monthly visits, where disease monitoring
is mandatory, and only in case of disease progression, the
patient would be retreated, ideally in a one-stop visit [8].
Different studies have evidenced that this PRN model is dif-
ficult to achieve in routine clinical practice due to the limi-
tations that the ophthalmology routine exercise have [12, 16].
Actually, with a quarter of the retina specialist workload fo-
cused on wAMD and a median of 15minutes for patient care
(including injection time), it is really difficult to achieve a strict
PRN dosing strategy. In addition, considering that the most
frequently used monitoring tests in Spain (slit lamp fundus
examination, OCT, and Snellen test) would be conducted with
a mean frequency of 8weeks, it seems clear that the strict PRN
protocol could not be appropriately conducted in routine
clinical practice, as was confirmed by the panelists.
Recent studies indicate that a decrease inmonitoring and
injection frequency could not necessarily be related to
negative impact on wAMD outcomes [24]. .en, strict PRN
protocols could not be cornerstones for a successful wAMD
management. Depending on disease progression and
treatment response, the interval between injections could be
progressively increased and even treatment could be com-
pletely stopped in case of disease stabilisation for more than
12months [26]. In this regard, T&E strategies could be
identified as optimal for wAMD management, in agreement
with the opinion of our panelists.
T&E regimen could be defined as an individualized
proactive dosing strategy, whose driver is the adaptation of
the treatment regimen and visits interval according to disease
activity, with the aim to achieve optimal outcomes [24, 26],
similar to that provided with regular fixed dosing regimens
[28, 29], but usually with a lower need for healthcare re-
sources. However, the success of this strategy depends on the
ability to perform the preplanned visits and effective treat-
ment injection schedule, which is the main challenge in our
current routine clinical practice and the main reason for
defining this strategy as “flexible” for most of the panelists.
Delphi results evidenced many limitations that need to
be addressed regarding wAMD management in Spain. In
addition to the retina specialists overload and the lack of
supporting staff that could be useful to optimise healthcare
professional resources, the management of wAMD patients
is affected by structural and organisational issues of the
centres, making it difficult to schedule and conduct regular
preplanned administration of intravitreal injections, one-
stop management models, and appropriate treatment in-
jection facilities, overall leading to long waiting periods from
visit to injection administration (healthcare overload)..en,
conducting to “flexible” management strategies for wAMD
patients agreed as not effective enough.
Although these are the main issues identified in the Spanish
context, they are not exclusive from Spain [25]. Other countries
have also identified similar issues, agreeing in the need for
investment inwAMDmanagement [11, 30], with focus on better
coordination among healthcare teams, workload reduction for
retina specialists by increasing the involvement of optometrists
or nurses in themanagement of wAMDpatients, favouring one-
stop model and the regular patient follow-up, with the aim of
improving healthcare results.
Apart from the need for resources optimisation, treat-
ment patterns could be supported by the use of drugs that
favour timings adaptation and minimising the need for
changing routine daily clinical practice and associated in-
vestment. In this regard, the use of drugs with a VEGF
suppression longer than one month could have the potential
to better suit to a proactive T&E regimen with a minor
impact on resources [24]. .ese therapeutic options could
potentially facilitate the appropriate implementation of strict
T&E regimens that could improve treatment outcomes in
routine clinical practice [27], achieving similar responses to
those reported in the clinical trials [27, 29, 31] and agreeing
with the opinion and experience of the study panelists re-
garding anti-VEGF choice.
.e results of the present study showed that the
healthcare reality in Spain has evolved from previous studies
conducted in this country [12, 16], and it is similar to that
observed in other countries despite the limitations of a
Delphi study of these characteristics. Data provided in the
study reflected the experience of 49 retina specialists rep-
resenting their routine activity in themanagement of wAMD
patients in Spain. All data were collected based on an ac-
curate literature search and reviewed by a Steering Com-
mittee formed by reference Spanish retina specialists that
confirmed results coherence according to their own expe-
rience and in agreement with data reported in the previous
Delphi study performed in Spain [16], showing some im-
provement in the patient’s management due to the adoption
of proactive treatment strategies such as T&E and the
authorisation of new therapeutic agents in the wAMD
market. In addition, data were also confirmed by Delphi
participants that validated the results provided in the first
round by means of the answers of the second round.
Although data provided in this study should be con-
firmed by clinical charts and visit registries from healthcare
centres, it seems clear that wAMD management is not
optimal in most healthcare centres even though, in most
cases, there exists the initiative to adopt proactive models for
wAMD management. .e use of agents allowing longer
treatment intervals could help, but the results of this study
indicate that additional organisational changes and re-
sources reallocation beyond financial investment could be
necessary, in order to provide a real improvement in the
management of wet AMD patients, favouring the effective
implementation of a T&E strategy.
8 Journal of Ophthalmology
5. Conclusions
Anti-VEGF administration is the cornerstone for wAMD
treatment, based on a loading dose followed by a long-term
treatment until disease stabilization. Traditionally, reactive
treatment regimens were the standard procedure for wAMD
management, usually focused on PRN dosing strategies.
However, PRN regimen was linked to strict management
protocols difficult to address in routine clinical practice, where
healthcare resources are limited. Organisational healthcare
limitations together with staff workload are the main reasons
why neither monthly visit nor one-stop visits for immediate
retreatment could be conducted. .en, evolution to proactive
treatment models (T&E) became a priority in this situation,
especially considering the potential advantages in terms of
appointment scheduling, healthcare resource management,
and increasing the interval period between visits.
In this regard, as healthcare outcomes are linked to a
regular administration of the intravitreal therapy, mostly on
a proactive regimen basis, such as T&E, the use of drugs
allowing long administration intervals could contribute to
the wAMD management optimisation in routine clinical
practice. In addition, optimal and preplanned drug ad-
ministration frequencies could contribute to an improve-
ment of the workload for retina specialists and the possibility
for a regular one-stop administration of these therapies with
a minimum impact on the centre’s resources.
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